REG - RTW Biotech Opp. - Aktis announces $318 million IPO

RTW Biotech OpportunitiesAnnouncement

12/01/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260112:nRSL4168Oa&default-theme=true

RNS Number : 4168O  RTW Biotech Opportunities Ltd  12 January 2026

LEI: 549300Q7EXQQH6KF7Z84

12 January 2026

RTW Biotech Opportunities Ltd

Aktis announces $318 million IPO

·      First biotech IPO of 2026

·      IPO price represented 12.6% step-up to holding value and 18.3%
step-up from cost

·      As at 30 November, Aktis represented 0.6% of RTW Bio's NAV

 

RTW Biotech Opportunities Ltd ("RTW Bio"), the London Stock Exchange-listed
investment company focused on identifying transformative assets with high
growth potential across the life sciences sector, is pleased to note the
announcement by one of its private portfolio companies, Aktis Oncology, Inc.
("Aktis") regarding the pricing of its $318 million initial public offering
("IPO").

Aktis' IPO raised $318 million by offering 17.65 million shares at $18 per
share. This valuation represents a 12.6% step-up from RTW Bio's prior holding
value at 30 November 2025 and a 18.3% step-up from the cost at the time of
purchase in September 2024. Aktis began trading on the Nasdaq Global Select
Market under the ticker "AKTS" on 9 January 2026, where the stock traded up
24.4% to close at $22.40 per share.  As of 30 November 2025, Aktis
represented 0.6% of the RTW Bio's NAV.

Aktis is a clinical-stage oncology company focused on expanding the
breakthrough potential of targeted radiopharmaceuticals to large patient
populations. Its lead programme targets Nectin-4, a miniprotein radioconjugate
with multi-indication potential across multiple tumour types.

 

Rod Wong, CIO of RTW Investments, said, "We are thrilled to have supported the
first biotech IPO of the year, which marks a significant milestone for Aktis
and for the field of targeted radiopharmaceuticals. Aktis' rapid progress
reflects the transformative potential we seek in our portfolio companies and
underscores our commitment to identifying and supporting assets that drive
meaningful advances in patient care."

 

Aktis' announcement can be found here
(https://investors.aktisoncology.com/news-releases/news-release-details/aktis-oncology-announces-pricing-its-upsized-initial-public)
.

 

Enquiries:

 RTW Investments, LP - Investment Manager  +44 (0)20 7959 6362

 Oliver Kenyon                             biotechopportunities@rtwfunds.com

 Woody Stileman

 Krisha McCune (Investor Relations)

 Cadarn Capital - PR & IR Partner

 Lucy Clark (PR)                           +44 (0)7984 184 461 / lucy@cadarncapital.com

 David Harris (Distribution)               +44 (0)7368 883 211 / david@cadarncapital.com

 Deutsche Numis - Joint Corporate Broker   +44 (0)20 7260 1000

 Freddie Barnfield

 Nathan Brown

 Duncan Monteith

 BofA Securities - Joint Corporate Broker  +44 (0)20 7628 1000

 Edward Peel

 Alex Penney

 Altum (Guernsey) Limited                  +44 (0)1481 703 100

 Joanna Duquemin Nicolle

 Sadie Morrison

 

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on
identifying transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/)  for more
information.

 

***********

The information in this announcement may include forward-looking statements,
which are based on the current expectations and projections about future
events, and in certain cases can be identified by the use of terms such as
"may", "will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives thereon) or other
variations thereon or comparable terminology. These forward-looking
statements, as well as those included in any related materials, are subject to
risks, uncertainties and assumptions about the Company and/or its underlying
investments, including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use of financing
proceeds and future capital expenditures and acquisitions. In light of these
risks, uncertainties and assumptions, the events in the forward-looking
statements may not occur.

The information contained in this announcement is given at the date of its
publication (unless otherwise marked). No reliance may be placed for any
purpose whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or fairness.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PFUGPUMGGUPQUBU



            Copyright 2019 Regulatory News Service, all rights reserved